By Cara Murez and Robin Foster 

HealthDay Reporters

FRIDAY, Oct. 21, 2022 (HealthDay News) – In an unanimous vote on Thursday, a panel of U.S. vaccine specialists really helpful that COVID pictures be added to the listing of really helpful vaccinations for youngsters and adults.

Now it is as much as the U.S. Centers of Disease Control and Prevention to determine whether or not to observe the recommendation of its Advisory Committee on Immunization Practices.

Even if the company does approve including the pictures to the schedule, it would not quantity to a vaccine mandate. State and native jurisdictions will nonetheless determine what vaccines are required for colleges, NBC News reported.

“Moving COVID-19 to the really helpful immunization schedule doesn’t impression what vaccines are required for varsity entrance, if any,” stated Dr. Nirav Shah, director of the Maine Center for Disease Control and Prevention. “Local management issues. And we honor that the choice round faculty entrance for vaccines rests the place it did earlier than, which is with the state stage, the county stage and on the municipal stage, if it exists in any respect.”

“This dialogue doesn’t change that,” he instructed NBC News.

An instance of native jurisdictions making their very own decisions contains the HPV vaccine, which has been on the immunization schedule since 2006. Only Puerto Rico, Rhode Island and Washington, D.C., truly require it for each women and boys. Virginia requires the vaccine for women, NBC News reported.

Despite having a really helpful nationwide vaccine schedule, vaccination charges for American youngsters have dropped in the course of the pandemic.

COVID instances are additionally declining amongst U.S. youngsters, completely shut to twenty-eight,000 final week, in response to the American Academy of Pediatrics. It is the primary time since early April that instances have been beneath 30,000.

An benefit to having COVID-19 pictures on the vaccine schedule is that insurance coverage suppliers usually will cowl really helpful vaccines. Though federal {dollars} are nonetheless paying for these vaccines, that may finally finish, NBC News reported.

The COVID vaccines might additionally change into part of the federal Vaccines for Children program, which would supply them free to youngsters lined by Medicaid.

“By including it to the VFC program, it now makes these vaccines accessible to those uninsured and underinsured youngsters,” stated Dr. Julie Morita, govt vp of the Robert Wood Johnson Foundation, former public well being commissioner for Chicago and a former practising pediatrician.

Morita referred to as the schedule the “gold customary” for clinicians.

“I used to look yearly, ready for this vaccine schedule, to verify I used to be following the most effective vaccination steering accessible,” Morita instructed NBC News.

The post Add COVID Shot to Routine Vaccine Schedule: CDC Panel appeared first on Healthy and Slim Life.

By Cara Murez 

HealthDay Reporter

THURSDAY, Oct. 20, 2022 (HealthDay News) – Americans will now have one other alternative if they need a COVID booster shot.

On Wednesday, the U.S. Food and Drug Administration accredited Novavax Inc.’s protein-based vaccine as a primary booster dose. Until now, it had solely been accredited as a two-dose main sequence.

“The U.S. now has access to the Novavax COVID-19 Vaccine, adjuvanted, the first protein-based option, as a booster,” Novavax President and CEO Stanley Erck mentioned in a information launch. “According to CDC data, almost 50 percent of adults who received their primary series have yet to receive their first booster dose. Offering another vaccine choice may help increase COVID-19 booster vaccination rates for these adults.”

The Novavax booster may very well be utilized by adults who can’t discover or usually are not in a position to make use of an mRNA boosters from Pfizer or Moderna. It’s additionally accessible to individuals who want this vaccine for a booster over the mRNA choices. The Novavax booster could be given at the very least six months after the first sequence.

The Novavax vaccine makes use of a extra conventional strategy to combating the virus, instructing the immune system to acknowledge modified fragments of the coronavirus spike protein.

Scientists created the vaccine from a genetic sequence of the unique pressure of the virus. Vaccines that struggle hepatitis B and pertussis are additionally made on this method.

Public well being officers are encouraging individuals to get their boosters. About 68% of U.S. residents have had an preliminary COVID vaccine sequence, however solely 33.5% have acquired boosters, CDC information exhibits. Novavax’s vaccine is one in all 4 choices accessible within the United States now.

More info

The U.S. Centers for Disease Control and Prevention has extra on COVID-19 vaccines.

SOURCE: CNN

The post FDA OKs Novavax COVID Vaccine as First Booster Shot appeared first on Healthy and Slim Life.

March 15, 2022 — The CEO of vaccine maker Pfizer made information over the weekend when he mentioned individuals who have already gotten three pictures of his firm’s COVID-19 vaccine will want a fourth dose.

Albert Bourla, PhD, mentioned information the corporate has submitted to the FDA — however has not but launched publicly — reveals this want.

Although a 3rd dose of an mRNA vaccine can nonetheless reduce the dangers of hospitalization and demise, a fourth dose is “vital” to forestall future circumstances of an infection, he mentioned on CBS’s Face the Nation.

Pfizer can also be anticipated to ask the FDA this week to approve a fourth shot for folks 65 and older, The Washington Post reported Tuesday.

With all this taking place, we requested infectious illness consultants to weigh in, particularly as day by day new case numbers proceed to drop to ranges not seen since July 2021.

“To date, there’s restricted info surrounding the necessity or efficacy of a fourth dose of COVID-19 mRNA vaccines,” says Matthew Harris, MD.

A small research from Israel discovered {that a} fourth dose elevated antibodies to ranges larger than in sufferers who acquired three doses alone.

But the research didn’t discover a fourth dose efficient at stopping an infection from the Omicron variant, says, Harris, medical director of the Northwell Health COVID-19 vaccination program in New Hyde Park, NY.

“It appears a extra probably state of affairs that the COVID-19 vaccines will change into a part of a seasonal vaccination akin to the influenza vaccine,” he says.

Jason Pogue, PharmD, agrees {that a} fourth dose is extra a matter of “when” than “if.”

“Whether that’s with the vaccines at present out there, an Omicron-specific vaccine, a vaccine directed in direction of some future variant, or some mixture of these stays to be decided,” he says.

Ask Your Doctor

If you assume you may want or need a fourth shot, attain out to your physician or different well being care supplier, particularly if it has been 6 months or longer since your final shot.

At this time, the CDC recommends vaccination and a booster for everybody 12 and older and two doses for these 5 to 11. People with weakened immune programs are already inspired to get one other dose.

Harris recommends those that have been absolutely vaccinated and boosted for greater than 6 months to proceed to apply “good hand hygiene,” together with “masking and social distancing where appropriate, and frequent testing.”

Karen Tashima, MD, agrees it’s probably OK to attend for now.

“If sufferers are absolutely vaccinated and boosted, and transmission is low of their communities, I’d advise no additional vaccination for them,” she says.

While it’s true that after 6 months, safety from the vaccines and boosters begins to weaken towards an infection, you might be nonetheless “extremely well-protected against severe disease,” says Pogue, a clinical professor at the University of Michigan in Ann Arbor.

Fourth-Dose Fervor

How convincing will the Pfizer data supporting a fourth dose be? How much of a challenge will it be to get the “pandemic weary” to point out up for an additional COVID-19 vaccination within the close to future?

What is the chance that the worst of the pandemic is behind us within the U.S., particularly as circumstances of the Omicron subvariant BA.2 proceed to leap within the U.Ok. and throughout Europe?

The hashtag #Pfizer is trending on Twitter, with 126,000 tweets finally examine. Many individuals are commenting about Bourla’s name for a fourth vaccine dose on social media.

Reports about waning efficacy of COVID-19 vaccine boosters are nothing new. It appears inconceivable to ever know if Pfizer is being altruistic, business-minded, or a mixture of each. But optimistic information about an mRNA booster might be good for an organization’s backside line. For instance, Moderna shares jumped 11% final month when the corporate introduced a fourth dose of a COVID-19 vaccine will probably be wanted earlier than 12 months’s finish.

Better to Be Prepared?

“We do not know if a fourth dose shall be vital at this level,” says Tashima, an infectious ailments physician.

But she says it is vital to look at for any new outbreaks.

“If now we have new surges that trigger hospitalizations and demise, we might want to get one other dose. We ought to be ready for this chance,” she says.

It is smart, then, for the businesses making vaccines to be prepared with provides if wanted, says Tashima, director of medical trials at Miriam Hospital in Providence, RI.

The want for additional doses is predicated on a number of issues, Harris says. An enhance in variants, the charges of breakthrough infections, hospitalization and deaths associated to variants, and native charges of vaccination might additionally determine into the equation.

Any name for a fourth dose would have to be backed by information, he says.

“The present proof means that safety towards extreme illness, hospitalization, and demise stays fairly sturdy with three doses, with a number of studies suggesting a 90-99% discount in these outcomes with three doses,” Pogue says.

“Widespread administration of a fourth dose shouldn’t be going so as to add a notable benefit over these numbers.”

The post Pfizer’s CEO Says Fourth COVID Shot Is Needed. Is He Right? appeared first on Healthy and Slim Life.

By Robin Foster

HealthDay Reporter

THURSDAY, Jan. 27, 2022 (HealthDay News) — Moderna Inc. introduced Wednesday that it has launched a trial that can research the facility of a redesigned booster shot — one which hones in on the extremely contagious Omicron variant.

The information comes simply in the future after Pfizer introduced that it has began testing its personal Omicron-specific shot.

In asserting its trial, Moderna additionally defined why the newly formulated shot is required: A small lab research revealed Wednesday within the New England Journal of Medicine suggests the safety that Moderna’s licensed booster shot gives towards Omicron fades in six months’ time.

After a single dose of the present booster, the extent of Omicron-fighting antibodies rose 20 instances larger than their peak earlier than the shot, the corporate stated. But these antibody ranges had fallen greater than sixfold six months later, although they have been nonetheless detected in all the booster recipients within the research.

“We are reassured by the antibody persistence towards Omicron at six months after the at present licensed 50 µg booster of mRNA-1273. Nonetheless, given the long-term risk demonstrated by Omicron’s immune escape, we’re advancing our Omicron-specific variant vaccine booster candidate,” Moderna CEO Stéphane Bancel stated in an organization assertion.

Although Omicron can evade the antibodies elicited by licensed vaccines, making breakthrough infections extra widespread, the vaccines nonetheless present sturdy safety towards hospitalization and loss of life, a number of research have already proven.

Moderna’s new research will give attention to a single Omicron-specific booster dose in about 600 adults, damaged into two teams: Those who’ve acquired two doses of Moderna’s present vaccine, and people have acquired two doses plus a booster.

The firm didn’t say when outcomes could possibly be anticipated.

Pfizer, which plans to enroll as many as 1,420 folks in its research, stated it expects to have ends in the primary half of this yr.

Both Omicron-specific booster photographs are being developed because the Omicron variant establishes its dominance on this nation: The newest information from the U.S. Centers of Disease Control and Prevention present that 99.9% of U.S. COVID instances at the moment are pushed by the extremely transmissible variant.

More info

Visit the U.S. Food and Drug Administration for extra on COVID vaccines.

SOURCE: Associated Press, The New York Times

WebMD News from HealthDay

Copyright © 2013-2022 HealthDay. All rights reserved.

The post Moderna Begins Testing Booster Shot Aimed at Omicron appeared first on Healthy and Slim Life.

Nov. 24, 2021– As vaccinations amongst kids ages 5-11 choose up steam, a major variety of mother and father say they are not looking for their youngsters vaccinated.

In a ballot of WebMD readers, 49% of these responding who’ve kids in that age group say they are not looking for their little kids to get the COVID-19 vaccine.

On Nov. 2, CDC Director Rochelle P. Walensky, MD, endorsed an company advisory panel’s suggestion that kids 5-11 be vaccinated with the Pfizer pediatric vaccine. That determination expanded vaccine suggestions to about 28 million kids within the United States.

Vaccinations among the many not too long ago eligible 5- to 11-year-olds have steadily elevated after a considerably gradual begin. At first, the tempo was behind that of the 12- to 15-years-olds by means of the primary week of eligibility, however it has since closed the hole, based mostly on information from the CDC’s COVID Data Tracker.

Altogether, simply over 3 million kids ages 5-11 have obtained no less than one dose, which is 10.7% of that age group’s complete inhabitants.

The CDC says that the Pfizer vaccine was greater than 90% efficient in stopping COVID-19 an infection in kids 5 to fifteen years previous, and that the immune response in kids ages 5-15 equaled the immune response in individuals 16 to 25 years previous.

Among individuals general within the WebMD ballot, 56% mentioned they have been assured or considerably assured that the vaccine is protected for that age group.

Among adolescents and younger adults, uncommon circumstances of myocarditis and pericarditis have been reported. According to the CDC, “[I]n one research, the chance of myocarditis after the second dose of Pfizer-BioNTech within the week following vaccination was round 54 circumstances per million doses administered to males ages 12-17 years.”

Known and potential advantages of COVID-19 vaccination outweigh the dangers, together with the attainable danger for myocarditis or pericarditis, the CDC says.

Concerns Also Among Doctors, Nurses

A companion ballot of medical doctors and nurses on Medscape, WebMD’s sister web site for well being care professionals, additionally discovered vital hesitation to the youngsters’s vaccines.

Among medical doctors who’ve kids in that age group, 30% of respondents mentioned they’d not need their kids to be vaccinated; 9% have been not sure. For nurses and superior follow registered nurses (APRNs), 45% mentioned they didn’t need their youngsters to get the COVID-19 vaccine; 13% have been not sure. Among pharmacists, 31% mentioned they’d not get them vaccinated and 9% have been not sure.

How Safe Is the Vaccine?

Clinicians have been requested how assured they have been that the vaccine is protected for that age group, and 66% of physicians, 52% of nurses/APRNs, and 66% of pharmacists mentioned they have been considerably or very assured.

Across clinician sorts, girls edged out their male counterparts on confidence within the vaccine’s security: 71% vs. 65% amongst medical doctors, 55% vs. 45% amongst nurses/APRNs, and 68% vs. 60% amongst pharmacists.

Among each medical doctors and nurses, youthful medical doctors (beneath 45) tended to have better confidence within the vaccine’s security: 72% vs 64% (medical doctors), 54% vs 51% (nurses/APRNs), and 71% vs 59% (pharmacists).

The distinction in confidence was clear between vaccinated and unvaccinated medical doctors. All of the unvaccinated medical doctors who responded to the ballot mentioned they’d no confidence within the vaccine for teenagers. Among unvaccinate

The post 49% of Parents of Kids 5-11 Reject COVID Shot for Them appeared first on Healthy and Slim Life.

TUESDAY, Oct. 12, 2021 (HealthDay News) — Experts are warning that the upcoming flu season may very well be extreme as social distancing measures are relaxed throughout the United States, however a brand new survey finds that 6 in 10 Americans could delay or skip a flu shot.

However, it additionally discovered that 98% of those that received a flu shot final season do plan to get one once more this 12 months.

While 82% of the 1,000 grownup members of the net survey mentioned they’re considering extra about their well being resulting from COVID-19, solely 26% mentioned COVID-19 makes them extra more likely to get a flu shot this 12 months.

Hispanics have been extra more likely to say COVID-19 had an influence on their flu shot determination (57%) than non-Hispanics (38%), based on the ballot from the American Heart Association (AHA).

“If there has ever been a 12 months to prioritize getting your flu shot initially of the season, that is it,” AHA President Dr. Donald Lloyd-Jones mentioned in an affiliation information launch. “The flu can be again this 12 months, and getting the flu vaccine as quickly as doable will supply probably the most safety for you and your family members.

“The flu virus goes to have a neater time spreading this 12 months with extra individuals out and about at college, church, sporting occasions and so forth. It’s extremely vital so that you can get the flu vaccine this 12 months and be sure to and your family members are protected,” mentioned Lloyd-Jones, chair of the Department of Preventive Medicine at Northwestern University Feinberg School of Medicine in Chicago.

Getting the flu vaccination will assist forestall a “twindemic” and decrease your danger of dealing with a one-two punch of extreme flu and extreme COVID-19 collectively or back-to-back, he famous.

“We suggest the flu shot for primarily everybody and notably individuals who is likely to be weak as a result of they’ve power well being circumstances — issues like diabetes, hypertension or weight problems — in addition to people who find themselves more likely to be extra-exposed, like well being care employees and people who find themselves working in an important front-line job the place they arrive into contact with numerous completely different individuals,” Lloyd-Jones mentioned.

The U.S. Centers for Disease Control and Prevention recommends getting a flu shot by Oct. 31 for the very best seasonal safety, and recommends the influenza vaccine for everybody 6 months of age and older, with just a few exceptions.

More info

The U.S. Centers for Disease Control and Prevention has extra on the flu shot.

SOURCE: American Heart Association, information launch, Oct. 12, 2021

The post 60% of Americans Will Delay or Skip Flu Shot This Year appeared first on Healthy and Slim Life.

Oct. 15, 2021 — A FDA advisory committee on Friday voted 19-0 to authorize second doses of the Johnson & Johnson COVID-19 vaccine in an effort to spice up immunity. It was the second vote in as many days to again a change to a COVID vaccine timeline.

In its vote, the committee stated that boosters could possibly be supplied to individuals as younger as age 18. However, it’s not clear that everybody who acquired a Johnson & Johnson vaccine must get a second dose.  The identical panel voted Thursday to advocate booster pictures for Moderna vaccine, however for a narrower group of individuals.

It shall be as much as a CDC panel subsequent week to make extra particular suggestions for who may want one other shot. The CDC’s Advisory Committee on Immunization Practices is scheduled to fulfill subsequent Thursday to debate points associated to COVID-19 vaccines.

Studies of the effectiveness of the J&J vaccine in the true world present that its safety — whereas good — has not been as sturdy because the mRNA vaccines made by Pfizer and Moderna, that are given as a part of a two-dose collection.

In the tip, the members of the Vaccines and Related Biological Products Advisory Committee stated they felt that the corporate hadn’t made a case for calling their second shot a booster, however had proven sufficient information to counsel that everybody over the age of 18 ought to take into account getting two pictures of the Johnson & Johnson vaccine as a matter in fact.

This is an particularly necessary difficulty for adults over the age of fifty. A current research in TheNew England Journal of Medicine discovered that older adults who acquired the Johnson & Johnson vaccine had been much less protected in opposition to an infection and hospitalization than those that acquired mRNA vaccines.

Limited Data

The firm offered information from six research to the FDA panel in help of a second dose had been restricted. The solely research second doses after 6 months included simply 17 individuals.

These research did present {that a} second dose considerably elevated ranges of neutralizing antibodies, that are the physique’s first line of safety in opposition to COVID-19 an infection.

But the corporate turned this information over to the FDA so not too long ago that company scientists repeatedly burdened throughout the assembly that they didn’t have ample time to observe their regular means of independently verifying the information and following up with their very own evaluation of the research outcomes.

Peter Marks, MD, director of the FDA’s Center for Biologics Evaluation and Research, stated it might have taken months to finish that rigorous degree of evaluation.

Instead, within the curiosity of urgency, the FDA stated it had tried to deliver some readability to the tangle of research outcomes offered that included three dosing schedules and completely different measures of effectiveness.

 “Here’s how this strikes me,” stated committee member Paul Offit, MD, a professor of pediatrics and infectious illness at Children’s Hospital of Philadelphia. “I think this vaccine was always a two-dose vaccine. I think it’s better as a two-dose vaccine. I think it would be hard to recommend this as a single-dose vaccine at this point.”

“As far as I’m involved, it was all the time going to be mandatory for J&J recipients to get a second shot.” stated James Hildreth, MD, PhD, the president and CEO of Meharry Medical College in Nashville, Tennessee.

Archana Chatterjee, MD, dean of the Chicago Medical School at Rosalind Franklin University stated she had modified her vote throughout the course of the assembly. 

She stated that primarily based on the very restricted security and effectiveness information offered to the committee, she was ready to vote in opposition to the concept of providing second doses of Johnson & Johnson pictures.

But after contemplating the 15 million individuals who have been vaccinated with a single dose and research which have urged shut to five million older adults should be in danger for hospitalization as a result of they’ve simply had one shot, “This is still a public health imperative,” she stated.

“I’m in agreement with most of my colleagues that this second dose, booster, whatever you want to call it, is necessary in these individuals to boost up their immunity back into the 90-plus percentile range,” she stated.

Who Needs a Second Dose?

Thursday, the committee heard an replace on information from Israel, which noticed a wave of extreme breakthrough infections throughout the Delta wave. 

COVID-19 circumstances are falling quickly there after the nation extensively deployed booster doses of the Pfizer vaccine.

On Friday, the Marks from the FDA stated the company was leaning towards creating better flexibility within the emergency use authorizations for the Johnson & Johnson and Moderna vaccines in order that boosters could possibly be extra extensively deployed within the U.S., too.

The FDA panel on Thursday voted to authorize a 50-milligram dose of Moderna’s vaccine — half the dose used within the major collection of pictures — to spice up immunity not less than 6 months after the second dose. Those who may want a booster are the identical teams who’ve gotten a inexperienced gentle for third Pfizer doses, together with individuals over 65, adults at greater threat of extreme COVID-19 and people who are at greater threat due to the place they stay or work.

The FDA requested the committee on Friday to debate whether or not boosters ought to be supplied to youthful adults, even these with out underlying well being circumstances. 

“We’re concerned that what was seen in Israel could be seen here,” Marks stated. “We don’t want to have a wave of severe COVID-19 before we deploy boosters.”

Some members of the committee cautioned Marks to watch out when increasing the EUAs, as a result of it might confuse individuals.

“When we say immunity is waning, what are the implications of that?” stated Michael Kurilla, MD, director of the Division of Clinical Innovation on the National Institutes of Health.

Overall, information present that every one the vaccines at the moment getting used within the U.S. — together with Johnson & Johnson — stay extremely efficient for stopping extreme outcomes from COVID-19, like hospitalization and dying.

Booster doses might forestall extra individuals from even getting gentle or reasonable signs from “breakthrough” COVID-19 circumstances, which started to rise throughout the current Delta surge. They are additionally anticipated to forestall extreme outcomes like hospitalization in older adults and people with underlying well being circumstances.

“I think we need to be clear when we say waning immunity and we need to do something about that, I think we need to be clear what we’re really targeting [with boosters] in terms of clinical impact we expect to have,” Kurilla stated.

Others identified that stopping even gentle to reasonable infections was a worthy aim, particularly contemplating the implications of long-haul COVID-19

“COVID does have tremendous downstream effects, even in those who are not hospitalized. Whenever we can prevent significant morbidity in a population, there are advantages to that,” stated Steven Pergam, MD, medical director of an infection prevention on the Seattle Cancer Care Alliance.

“I’d really be in the camp that would be moving towards a younger age range for allowing boosters,” Pergam stated.

The post FDA Panel Backs Second Shot for Those Who Got J&J Vaccine appeared first on Healthy and Slim Life.